Skip to main content

Table 1 Clinical characteristics of the included datasets

From: Identification of an immune signature predicting prognosis risk of patients in lung adenocarcinoma

Features

TCGA (n, %)

GSE30219 (n, %)

GSE31210 (n, %)

GSE3141 (n, %)

GSE81089 (n, %)

Platform

Illumina HiSeq2000 RNA sequencing platform

Affymetrix Human Genome U133 Plus 2.0 Array

Affymetrix Human Genome U133 Plus 2.0 Array

Affymetrix Human Genome U133 Plus 2.0 Array

Illumina HiSeq2000 RNA sequencing platform

Age

 ≤ 60 y

157 (31.4%)

43 (50.6%)

108 (47.8%)

20 (18.5%)

 > 60 y

333 (66.6%)

42 (49.4%)

118 (52.2%)

88 (81.5%)

 NA

10 (2.0%)

0 (0.0%)

0 (0.0%)

0 (0.0%)

Gender

 Male

230 (46.0%)

66 (77.6%)

105 (46.5%)

39 (36.1%)

 Female

270 (54.0%)

19 (22.4%)

121 (53.5%)

69 (63.9%)

 NA

0 (0.0%)

0 (0.0%)

0 (0.0%)

0 (0.0%)

Recurrence

 Yes

155 (31.0%)

27 (31.8%)

64 (28.3%)

 No

285 (57.0%)

58 (68.2%)

162 (71.7%)

 NA

60 (12.0%)

0 (0.0%)

0 (0.0%)

AJCC stage

 Stage I

268 (53.6%)

168 (74.3%)

62 (57.4%)

 Stage II

119 (23.8%)

58 (25.7%)

19 (17.6%)

 Stage III

80 (16.0%)

0 (0.0%)

24 (22.2%)

 Stage IV

25 (5.0%)

0 (0.0%)

3 (2.8%)

 Stage X

8 (1.6%)

0 (0.0%)

0 (0.0%)

T stage

 T1

167 (33.4%)

71 (83.5%)

 T2

267 (53.4%)

12 (14.1%)

 T3

45 (9%)

2 (2.4%)

 T4

18 (3.6%)

0 (0.0%)

 TX

3 (0.6%)

0 (0.0%)

N stage

 N0

324 (64.8%)

82 (96.5%)

 N1–3

165 (33.0%)

3 (3.5%)

 NX

11 (2.2%)

0 (0.0%)

M stage

 M0

332 (66.4%)

85 (100%)

 M1

24 (4.8%)

0 (100%)

 MX

144 (28.8%)

0 (100%)

Survival status

 Alive

318 (63.6%)

40 (47.1%)

191 (84.5%)

26 (45.6%)

59 (54.6%)

 Dead

182 (36.4%)

45 (52.9%)

35 (15.5%)

31 (54.4%)

49 (45.4%)

  1. y years, TCGA The Cancer Genome Atlas